blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP4122926

EP4122926 - TRIAZINE DERIVATIVES HAVING VIRUS REPLICATION INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME [Right-click to bookmark this link]
Former [2023/04]TRIAZINE DERIVATIVE HAVING VIRUS PROPAGATION INHIBITORY EFFECT, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME
[2025/03]
StatusThe patent has been granted
Status updated on  02.05.2025
Database last updated on 01.04.2026
FormerGrant of patent is intended
Status updated on  19.01.2025
FormerExamination is in progress
Status updated on  05.12.2024
FormerGrant of patent is intended
Status updated on  01.08.2024
FormerExamination is in progress
Status updated on  14.03.2024
FormerRequest for examination was made
Status updated on  23.12.2022
FormerThe international publication has been made
Status updated on  02.07.2022
Most recent event   Tooltip02.05.2025(Expected) grantpublished on 04.06.2025  [2025/23]
02.05.2025Change - applicantpublished on 04.06.2025  [2025/23]
Applicant(s)For all designated states
Shionogi & Co., Ltd.
1-8, Doshomachi 3-chome
Chuo-ku
Osaka-shi, Osaka 541-0045 / JP
For all designated states
National University Corporation Hokkaido University
Kita 8-jyo Nishi 5-chome
Kita-ku
Sapporo-shi, Hokkaido 060-0808 / JP
[2025/23]
Former [2023/04]For all designated states
Shionogi & Co., Ltd
1-8, Doshomachi 3-chome
Chuo-ku
Osaka-shi, Osaka 541-0045 / JP
For all designated states
National University Corporation Hokkaido University
Kita 8-jyo Nishi 5-chome
Kita-ku
Sapporo-shi, Hokkaido 060-0808 / JP
Inventor(s)01 / TACHIBANA, Yuki
Osaka-shi, Osaka 541-0045 / JP
02 / UEHARA, Shota
Osaka-shi, Osaka 541-0045 / JP
03 / UNOH, Yuto
Osaka-shi, Osaka 541-0045 / JP
04 / NAKAHARA, Kenji
Osaka-shi, Osaka 541-0045 / JP
05 / TAODA, Yoshiyuki
Osaka-shi, Osaka 541-0045 / JP
06 / KASAMATSU, Koji
Osaka-shi, Osaka 541-0045 / JP
07 / YAMATSU, Yukiko
Osaka-shi, Osaka 541-0045 / JP
08 / ANDO, Shigeru
Osaka-shi, Osaka 541-0045 / JP
09 / IIMURO, Atsuhiro
Osaka-shi, Osaka 541-0045 / JP
10 / SUTO, Takahiro
Osaka-shi, Osaka 541-0045 / JP
11 / SASAKI, Michihito
Sapporo-shi, Hokkaido 060-0808 / JP
 [2023/04]
Representative(s)Vossius & Partner Patentanwälte Rechtsanwälte mbB
Siebertstraße 3
81675 München / DE
[2023/04]
Application number, filing date22733282.217.02.2022
[2023/04]
WO2022JP06495
Priority number, dateJP2021006867214.04.2021         Original published format: JP 2021068672
JP2021010580225.06.2021         Original published format: JP 2021105802
JP2021015381922.09.2021         Original published format: JP 2021153819
[2023/04]
Filing languageJA
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2022138987
Date:30.06.2022
Language:JA
[2022/26]
Type: A1 Application with search report 
No.:EP4122926
Date:25.01.2023
Language:EN
[2023/04]
Type: B1 Patent specification 
No.:EP4122926
Date:04.06.2025
Language:EN
[2025/23]
Search report(s)International search report - published on:JP30.06.2022
(Supplementary) European search report - dispatched on:EP31.07.2023
ClassificationIPC:C07D401/06, A61K31/506, A61K31/53, A61K31/5377, A61K31/5383, A61K31/55, A61P31/14, A61P43/00, C07D251/46, C07D401/04, C07D401/14, C07D403/06, C07D403/14, C07D405/14, C07D409/14, C07D413/14, C07D417/06, C07D417/14, C07D471/04
[2024/34]
CPC:
C07D403/14 (EP,CN,IL,KR,US); C07D401/14 (EP,CN,IL,US); A61K31/53 (KR,US);
A61K47/542 (US); A61K9/0019 (EP); A61K9/0053 (EP);
A61P31/14 (EP,CN,IL,KR,US); A61P43/00 (EP,IL); C07D401/04 (US);
C07D401/06 (US); C07D403/06 (EP,US); C07D405/14 (EP,US);
C07D409/14 (EP,US); C07D413/14 (EP,US); C07D417/06 (EP,US);
C07D417/14 (EP,US); C07D471/04 (EP,US); C07D487/04 (EP,US);
C07D495/04 (EP,US); C07D498/04 (EP,US); C07B2200/13 (KR,US);
Y02A50/30 (EP) (-)
Former IPC [2023/04]C07D401/06, A61K31/506, A61K31/53, A61K31/5377, A61K31/5383, A61K31/55, A61P31/14, A61P43/00, C07D251/46, C07D401/04, C07D401/14, C07D403/06, C07D403/14
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2023/04]
Extension statesBANot yet paid
MENot yet paid
Validation statesKHNot yet paid
MANot yet paid
MDNot yet paid
TNNot yet paid
TitleGerman:TRIAZINDERIVATE MIT VIRUSREPLIKATIONSHEMMENDER WIRKUNG UND DIESE ENTHALTENDE PHARMAZEUTISCHE ZUSAMMENSETZUNG[2025/07]
English:TRIAZINE DERIVATIVES HAVING VIRUS REPLICATION INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME[2025/07]
French:DÉRIVÉS DE TRIAZINE AYANT UNE ACTIVITÉ INHIBITRICE DE LA RÉPLICATION VIRALE ET COMPOSITION PHARMACEUTIQUE LES CONTENANT[2025/07]
Former [2023/04]TRIAZINDERIVAT MIT VIRUSVERMEHRUNGSHEMMENDER WIRKUNG UND PHARMAZEUTISCHE ZUSAMMENSETZUNG DAMIT
Former [2023/04]TRIAZINE DERIVATIVE HAVING VIRUS PROPAGATION INHIBITORY EFFECT, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME
Former [2023/04]DÉRIVÉ DE TRIAZINE AYANT UN EFFET INHIBITEUR SUR LA PROPAGATION DE VIRUS, ET COMPOSITION PHARMACEUTIQUE LE CONTENANT
Entry into regional phase19.10.2022Translation filed 
19.10.2022National basic fee paid 
19.10.2022Search fee paid 
19.10.2022Designation fee(s) paid 
19.10.2022Examination fee paid 
Examination procedure19.10.2022Examination requested  [2023/04]
15.02.2024Amendment by applicant (claims and/or description)
15.02.2024Date on which the examining division has become responsible
13.03.2024Despatch of a communication from the examining division (Time limit: M04)
15.07.2024Reply to a communication from the examining division
02.08.2024Communication of intention to grant the patent
02.12.2024Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
20.01.2025Communication of intention to grant the patent
30.04.2025Fee for grant paid
30.04.2025Fee for publishing/printing paid
30.04.2025Receipt of the translation of the claim(s)
Divisional application(s)EP24168486.9  / EP4400502
Fees paidRenewal fee
03.01.2024Renewal fee patent year 03
06.01.2025Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[E] WO2023054732  (SHIONOGI & CO et al.) [E]
 [E] WO2023027198  (SHIONOGI & CO et al.) [E] 1-36 * claim 1 *
 [E] WO2023054292  (SHIONOGI & CO et al.) [E] 1-36 * claim 1 *
 [A] EP2604595  (SHIONOGI & CO et al.)
 [E]   AKAJI KENICHI ET AL: "Design and Evaluation of Anti-SARS-Coronavirus Agents Based on Molecular Interactions with the Viral Protease", MOLECULES, vol. 25, no. 17, 27 August 2020 (2020-08-27), pages 3920, XP055826867, DOI: 10.3390/molecules25173920

DOI:   http://dx.doi.org/10.3390/molecules25173920
International search[AX] CN102807568  (JIANGSU CHIA TAI TIANQING PHAR et al.) [A] 2, 3, 12, 15-17, 19-36 [X] 1, 4-11, 13, 14, 18
 [AX] CN104109147  (ANHUI YI XIN MING PHARMACEUTICAL CO LTD et al.) [A] 2, 3, 5, 12, 15-17, 19-36 [X] 1, 4, 6-11, 13, 14, 18
 [AX] JP2003520856   [A] 2, 3, 9-17, 19-36 [X] 1, 4-8, 18
 [AX] JP2016534027  (シャンハイ ヘンルイ ファーマスーティカル カンパニー リミテッドＳＨＡＮＧＨＡＩ ＨＥＮＧＲＵＩ ＰＨＡＲＭＡＣＥＵＴＩＣＡＬ ＣＯ．， ＬＴＤ． et al.) [A] 2, 10-36 [X] 1, 3-9
 [AX] JP2009531456   [A] 2, 3, 5, 12, 15-17, 19-36 [X] 1, 4, 6-11, 13, 14, 18
 [AX] JP2009508873   [A] 2, 3, 5, 12, 15-17, 19-36 [X] 1, 4, 6-11, 13, 14, 18
 [AX] JP2005263780  (SYRRX INC et al.) [A] 2, 3, 5, 12, 15-17, 19-36 [X] 1, 4, 6-11, 13, 14, 18
 [A] WO2012020749  (SHIONOGI & CO et al.) [A] 1-36 * examples *
 [AX]   ZENG-WEI LAI, CHUNHONG LI, JUN LIU, LINGYI KONG, XIAOAN WEN, HONGBIN SUN: "Discovery of highly potent DPP-4 inhibitors by hybrid compound design based on linagliptin and alogliptin", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, ELSEVIER MASSON SAS, vol. 83, 1 August 2014 (2014-08-01), pages 547 - 560, XP055149452, ISSN: 02235234, DOI: 10.1016/j.ejmech.2014.06.044 [A] 2, 3, 5, 12, 15-17, 19-36 [X] 1, 4, 6-11, 13, 14, 18

DOI:   http://dx.doi.org/10.1016/j.ejmech.2014.06.044
 [AXX]   DATABASE REGISTRY 2 December 2011 (2011-12-02), ANONYMOUS : "2,4(1H,3H)-Pyrimidinedione, 1,5-bis[(2,6-difluorophenyl)methyl]-3-[(1R)-2- [[(2-ethoxyphenyl)methyl]amino]-1-methylethyl]-6-methyl- (CA INDEX NAME)", XP055946826, retrieved from STN Database accession no. 1347270-26-1 [A] 2, 3, 6, 10-12, 15-36 [X] 1, 4, 5, 7-9, 13, 14 [X] 1, 4, 5, 7-9, 13, 14
 [A]   LIU YUZHI; LIANG CHENGYUAN; XIN LIANG; REN XIAODONG; TIAN LEI; JU XINGKE; LI HAN; WANG YONGBO; ZHAO QIANQIAN; LIU HONG; CAO WENQIA: "The development of Coronavirus 3C-Like protease (3CLpro) inhibitors from 2010 to 2020", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, ELSEVIER, AMSTERDAM, NL, vol. 206, 6 August 2020 (2020-08-06), AMSTERDAM, NL , XP086299093, ISSN: 0223-5234, DOI: 10.1016/j.ejmech.2020.112711 [A] 1-36 * table 5 *

DOI:   http://dx.doi.org/10.1016/j.ejmech.2020.112711
by applicantWO2012020749
 WO2013089212
 WO2010092966
 WO2014200078
 WO2012009258
 WO2021205298
 WO2021250648
 CN113620888
 CN113666914
 CN113735838
 CN113773300
 CN113801097
 WO2012020742
 WO2013118855
   "COVID-19 Dashboard by the Center for Systems Science and Engineering at Johns Hopkins University", 28 January 2022, JOHNS HOPKINS UNIVERSITY
   THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 382, 2020, pages 1564 - 1567
   WHO, REPORT OF THE WHO-CHINA JOINT MISSION ON CORONAVIRUS DISEASE 2019 (COVID-19, 28 February 2020 (2020-02-28), Retrieved from the Internet
   SCIENCE, vol. 300, 2003, pages 1763 - 1767
   "A comparative analysis of SARS-CoV-2 antivirals characterizes 3CLpro inhibitor PF-00835231 as a potential new treatment for COVID-19", JOURNAL OF VIROLOGY, 26 April 2021 (2021-04-26), Retrieved from the Internet
   CELL RESEARCH, vol. 30, 2020, pages 678 - 692
   SCIENCE, vol. 368, 2020, pages 409 - 412
   ACS CENTRAL SCIENCE, vol. 7, no. 3, 2021, pages 467 - 475
   CANCER TREATMENT REVIEWS, vol. 11, 1984, pages 99 - 110
   CONTRIBUTIONS TO ONCOLOGY, vol. 18, 1984, pages 221 - 234
   ARZNEIMITTEL-FORSCHUNG, vol. 11, no. 6, 1984, pages 663 - 668
   261ST AM CHEM SOC (ACS) NATL MEET, 5 April 2021 (2021-04-05)
   SCIENCE, vol. 374, 2021, pages 1586 - 1593
   "Pfizer's Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk Of Hospitalization Or Death By 89% In Interim Analysis Of Phase 2/3 EPIC-HR Study", PFIZER PRESS RELEASE, 5 November 2021 (2021-11-05), Retrieved from the Internet
   "Isotopes in the Physical and Biomedical Sciences", vol. 1, 1987, article "Labeled Compounds"
   "Design of Prodrugs", 1985, ELSEVIER
   TOSHIO SAKURAI: "Guidance on X-ray Structural Analysis", 1983, SHOKABO CO., LTD.
   STOUTJENSEN: "X-Ray Structure Determination: A Practical Guide", 1968, MACMILLAN CO
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.